Lauren Beaver
Pain Medicine · Winston Salem, NCNPI 1124571674
Payments from drug & device makers
Across 703 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$694
- Lundbeck LLC$512
- E.r. Squibb & Sons, L.L.C.$429
- Novartis$406
- plus $5K from 49 others
What the payments were for
- Food & beverage$10,722100%
- Education$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,767 in reported general payments places this provider in the 75th percentile of 182 pain medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 241 | $420,996 |
| VraylarCariprazine Hcl | 260 | $413,138 |
| AustedoDeutetrabenazine | 25 | $150,322 |
| IngrezzaValbenazine Tosylate | 16 | $138,264 |
| TrintellixVortioxetine Hydrobromide | 81 | $85,879 |
| CaplytaLumateperone Tosylate | 34 | $67,678 |
| Abilify MaintenaAripiprazole | 17 | $50,774 |
| Invega SustennaPaliperidone Palmitate | 14 | $41,910 |
| VyvanseLisdexamfetamine Dimesylate | 90 | $34,689 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 580 | $28,518 |
| Vilazodone Hcl | 193 | $26,016 |
| BelsomraSuvorexant | 44 | $19,451 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 564 | $19,144 |
| Clonazepam | 1,293 | $15,140 |
| Lisdexamfetamine Dimesylate | 85 | $14,369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $694 | $471,771258 claims |
| AbbVieVraylar | $3,098 | $413,138260 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $30 | $150,32225 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $298 | $138,26416 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $139 | $120,568171 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,087 | $67,67834 claims |
| Johnson & JohnsonInvega Sustenna | $173 | $41,91014 claims |
| MerckBelsomra | $185 | $19,45144 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $12 | $4,36022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 182 pain medicine providers in North Carolina.
Other pain medicine in Winston Salem
- Leonardo KapuralWinston Salem$4.1M
- James NorthWinston Salem$3.7M
- Richard RauckWinston Salem$1.7M
- Christopher GilmoreWinston Salem$1.3M
- Jeffrey PeacockWinston Salem$553K
- Daniel BintrimWinston Salem$39K
- Binit ShahHuntersville$863K
- Courtney AumanJacksonville$210K
- Javid BakshAsheville$202K
- David ZubLeland$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.